FDA approves alternative storage conditions for EGRIFTA ™

January 21, 2013

Theratechnologies Inc. (TSX: TH) (NASDAQ: THER) announced today that the U.S. Food and Drug Administration (FDA) has granted approval of a Supplemental New Drug Application (sNDA), filed by its commercial partner, EMD Serono, Inc., providing for the revision of the EGRIFTA™ (tesamorelin for injection) prescribing information, to include storage conditions for the 2 mg vial up to 12 weeks at or below 25°C after dispensing to the patient.